192 related articles for article (PubMed ID: 25118879)
1. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Yu P; Petrus MN; Ju W; Zhang M; Conlon KC; Nakagawa M; Maeda M; Bamford RN; Waldmann TA
Leukemia; 2015 Mar; 29(3):556-66. PubMed ID: 25118879
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Chen J; Zhang M; Ju W; Waldmann TA
Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
5. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
7. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Tan C; Waldmann TA
Cancer Res; 2002 Feb; 62(4):1083-6. PubMed ID: 11861386
[TBL] [Abstract][Full Text] [Related]
9. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
10. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.
Pancewicz J; Taylor JM; Datta A; Baydoun HH; Waldmann TA; Hermine O; Nicot C
Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16619-24. PubMed ID: 20823234
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Karthik S; Sankar R; Varunkumar K; Ravikumar V
Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
[TBL] [Abstract][Full Text] [Related]
12. Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia.
Ju W; Zhang M; Petrus M; Maeda M; Pise-Masison CA; Waldmann TA
Retrovirology; 2014 Jun; 11():43. PubMed ID: 24890041
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
Zhang M; Zhang Z; Goldman CK; Janik J; Waldmann TA
Blood; 2005 Feb; 105(3):1231-6. PubMed ID: 15383455
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
18. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells.
Hamamura RS; Ohyashiki JH; Kurashina R; Kobayashi C; Zhang Y; Takaku T; Ohyashiki K
Br J Cancer; 2007 Oct; 97(8):1099-105. PubMed ID: 17895889
[TBL] [Abstract][Full Text] [Related]
19. Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Karthik S; Sankar R; Varunkumar K; Anusha C; Ravikumar V
Biomed Pharmacother; 2015 Feb; 69():337-44. PubMed ID: 25661379
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
